Zanubrutinib for the treatment of patients with del(17p) and/or <i>TP53</i> CLL/SLL: analysis across clinical studiesConstantine S. Tam, Jennifer R. Brown, Alessandra Tedeschi et al.|Blood Advances|2025Cited by 2